BiotechTube

Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose) + Comparator: placebo

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

AIDS

Conditions

AIDS, HIV Infections

Trial Timeline

Nov 1, 2004 → Sep 1, 2009

NCT ID
NCT00095576

About Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose) + Comparator: placebo

Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose) + Comparator: placebo is a phase 2 stage product being developed by Merck for AIDS. The current trial status is terminated. This product is registered under clinical trial identifier NCT00095576. Target conditions include AIDS, HIV Infections.

What happened to similar drugs?

4 of 11 similar drugs in AIDS were approved

Approved (4) Terminated (1) Active (7)
✅TruvadaGilead SciencesApproved
✅bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + Standard initiation of antiretroviral therapy (ART)Gilead SciencesApproved
✅Emtricitabine and TenofovirGilead SciencesApproved
✅Maraviroc + Vardenafil + Maraviroc + PlaceboPfizerApproved
🔄EsomeprazoleAstraZenecaPhase 3
🔄EsomeprazoleAstraZenecaPhase 3
🔄Recombinant Human Papillomavirus Nonavalent VaccineMerckPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00095576Phase 2Terminated

Competing Products

20 competing products in AIDS

See all competitors
ProductCompanyStageHype Score
EsomeprazoleAstraZenecaPhase 3
40
EsomeprazoleAstraZenecaPhase 3
40
SelumetinibAstraZenecaPhase 1/2
24
MetforminMerckPhase 2/3
34
Recombinant Human Papillomavirus Nonavalent VaccineMerckPhase 3
40
rituximab + CHOPRochePhase 2
27
R-EPOCH and cARTRochePhase 2
35
Elvitegravir, Cobicistat, TAF, FTC + Efavirenz, TDF, and 3TCGilead SciencesPre-clinical
18
Switch to E/C/FTC/TAF dailyGilead SciencesPhase 1/2
32
Biktarvy + SymtuzaGilead SciencesPhase 3
40
TruvadaGilead SciencesApproved
43
ATV + DRV + Cobicistat + BR + F/TAF + LPV/r + Third Unboosted Drug + Cobicistat TOS + F/TAF TOSGilead SciencesPhase 2/3
42
bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + Standard initiation of antiretroviral therapy (ART)Gilead SciencesApproved
35
ChAdOx1.HTI + MVA.HTI + GS-9620 + Placebo + Placebo Oral TabletGilead SciencesPhase 2
35
E/C/F/TAF + E/C/F/TAF (Low Dose)Gilead SciencesPhase 2/3
38
EVG + Background regimenGilead SciencesPhase 2/3
30
Emtricitabine and TenofovirGilead SciencesApproved
39
TDF/FTC 300mg/200mg fixed-dose combination tablets + TAF/FTC 25mg/200mg fixed-dose combination tabletsGilead SciencesPhase 3
47
MaravirocPfizerPhase 1
29
Maraviroc + Vardenafil + Maraviroc + PlaceboPfizerApproved
43